India is building ADAS demand and safety mandates without any domestic LiDAR or perception-chip supply, so it will import Chinese sensors — cheap and safer for buyers, but repeating the solar and rare-earth dependence trap.

RoboSense turned profitable in Q4 on ~910k units and a 1mn-unit European order book, and in early 2026 shipped more sensors into robots than cars, positioning it under the robot economy.

Hesai industrialised LiDAR onto cheap silicon, shipped 1.6mn units in 2025 to reach the industry's first full-year profit, and now owns scale, patents and European design wins, with robotics as a second growth curve.

Companies posting 15%+ YoY sales growth, 20%+ profit growth and expanding operating margins for several consecutive quarters are genuinely compounding earnings, and a re-rating usually follows; annual CAGR, ROCE, low debt and CFO filters strip out one-off or commodity-driven noise.

Long-term AI compute demand is attractive, but the author doubts that every company buying GPUs will earn attractive returns, so capacity expansion alone does not justify the investment.

High crude and retail fuel under-recovery are making IOC, BPCL and HPCL lose ₹8–9/litre; excise cuts and pump hikes have not stopped the losses.

India's medical device market is over 70% import-dependent and a wave of cheap Chinese 4K endoscopes will deepen that reliance, shifting dependence from Tokyo to Beijing; India lacks procurement policy to build a domestic champion.

Portfolio weight increased meaningfully, making it one of the larger bets, though no explicit reasoning for the added conviction is given in this excerpt.

Allocation was increased, flagged as one of the bigger bets in the portfolio, but the text offers no supporting argument for the position.

Position cut sharply near ₹700 ahead of results because the combination of oversized weight, rich valuation and poor liquidity made the holding uncomfortable — a cautionary, valuation-driven trim rather than a growth call.

Lending benefits from perennial demand for money and low Indian credit penetration, offering growth, but it is cyclical and risky; prefer lenders with durable cost, yield, efficiency or credit-cost advantages that survive downturns.

Grid capex through 2032 plus a capacity doubling could sustain its margin jump, while unmonetized land worth ~957 cr covers roughly half the market cap — but at current prices it is a watchlist name, not a screaming buy.

Its Mumbai C&D plant ramped to or above capacity after BMC enforcement, and it is the only listed C&D plant operator near its 52-week low, giving direct exposure to mandatory recycled debris use.

India’s structural sand deficit and new C&D EPR rules mandate recycled debris use, while formal processing capacity covers only a small fraction of generation, creating a capacity-gap opportunity as enforcement and certificate demand ramp.

Long-term case rests on scaling the premium SMK brand and expanding global distribution, with exports and new capacity driving revenue; but margin recovery hinges on styrene/crude input costs stabilizing, so earnings stay pressured near term.

Revenue and export growth plus capacity addition support the story, but profitability is hostage to volatile styrene costs; margin recovery and the premium SMK brand scale-up are the swing factors, not yet proven.

India's ₹13,000 crore component incentive scheme arrives just as Beijing disciplines separator price wars, which modestly improves domestic plant economics — but India starts 15 years and one price war behind China's 90%+ share, 96% yields and boehmite chain.

Greenlam is a leading global laminate maker using brand and distribution to expand into fragmented plywood and adjacent wood-panel categories; near-term margins are pressured by capex, but capacity ramp-up can drive future growth and operating leverage.

Among non-SME, >50Cr profit stocks that doubled in a year, steel and precision steel pipes emerged as the most common recurring theme, alongside pockets of pharma, chemicals and jewellery.

In the crowded semaglutide market, Dr Reddy's supply/quality problem risks ceding customers to rivals; new sourcing-brand launches help but don't resolve the price competition.

Fully integrated non-ferrous metals play on India's copper/aluminium import dependence, with multiple re-rating triggers: Zambia copper cathode commissioning, CTC conductor import substitution, BIS approval, mainboard migration and improving cash generation.

Fully integrated copper/aluminium/brass processor with multiple re-rating triggers — Zambia copper cathode commissioning, import-substitute CTC conductors for EHV transformers, BIS approval and mainboard migration — trading at a reasonable valuation versus larger peers, though leverage is a risk.

Capacity expansion in Punjab and technical textiles could drive revenue and operating leverage, but the case depends on improving utilisation, EBITDA margins, PAT, ROCE and free cash flow after FY26 profit declined despite strong revenue growth.

An earnings-recovery and capacity-utilisation story: the Punjab plant ramp-up, integrated polyester-to-yarn manufacturing and technical textiles expansion could drive operating leverage and higher-value mix, but FY26 PAT fell ~52% despite 27% revenue growth, so returns must improve.

India's ambition to sequence 10mn genomes depends on cost it cannot achieve, and it makes none of the hardware — leaving the mission hostage to Chinese or Western suppliers and raising data-sovereignty exposure that is being decided by default procurement.

MGI crushed the cost of sequencing below $100 by re-engineering it as reusable-reagent heavy industry, holding 70% of China's market and narrowing losses; it is a scale-first disruptor targeting Illumina's 66% margins, though US BIOSECURE exclusion crimps its richest market.

RACL is a backward-integrated precision gear maker with deep OEM wallet share and new BMW, Royal Enfield, defence and EV projects that can diversify revenue and unlock growth.

India's electric-boat projects rely on imported powertrains and rare-earth magnets, so the real opportunity is building domestic marine-motor and magnet capability rather than remaining an assembly and import market.

India's headline market cap double counts listed subsidiaries inside listed parents by roughly ₹33 lakh Cr (~7%), so market-cap-to-GDP is overstated and drifts up with each subsidiary listing, making cross-year comparisons unreliable.

Asset-light grader paid a fee per report, so falling lab-grown diamond prices raise volumes rather than hurt it; it holds no inventory and dominates grading share. The stock de-rated to ~60x-to-bargain levels while profits kept compounding.

Steady margins mask severe price deflation for India's IT majors as clients demand AI productivity savings be passed on, compressing billable-hour revenue on routine work and forcing a shift to outcome-based pricing.

India's cable makers are world-class but import the ultra-pure XLPE compound, so scaling offshore wind and HV grid on imported insulation creates a supply chokehold; the Wanma-style playbook (domestic resin, cleanroom, state utility as first customer) is the missing piece.

The QSR downturn was largely cyclical rather than structural; with customers returning and same-store sales recovering, the earlier market pessimism looks overdone at current prices.

India's battery and solar build-out will run on cheap Chinese laser displacement sensors since no domestic precision-sensing industry exists, lowering automation costs but creating quiet upstream dependence on China.

India's record FDI inflows are largely offset by outflows via foreign parent stake sales and overseas M&A, and much of the money buys existing banks rather than greenfield factories or chip plants, so headline net FDI overstates durable productive investment.

India's shipbuilding push risks assembling hulls while importing mandatory environmental equipment from China; the value lies in domestic compliance-hardware and sensor/consumables manufacturing, not in slipways alone.

Store-led expansion (84 store FY27 guidance, 60 in H2), 20% SSSG and 64% Candere growth point to continued strong revenue momentum, aided by festive/wedding-season demand and a debt-free non-GML position.

Strong revenue growth, 20% SSSG, and aggressive store expansion, with H2 festive and wedding demand likely to support FY27 store guidance.

The author is testing whether the company's profit improvement reflects a genuinely better business rather than just a strong industrial cycle, with Q2 sales up 14% but profit down 5% leaving the question open.

Strong fundamentals — 52% ROCE, modest debt, a ₹1,780 crore order book up 195% YoY and EBITDA margins near 20% — but at ~29x trailing earnings much of the upcycle is already priced in, leaving limited margin of safety against cyclical order normalisation and Chinese competition.

India is heavily import-dependent on Chinese vitamins A, E and C, and its own fine-chemical firms lack NHU's process depth. The realistic opening for an Indian challenger is fermentation-based and natural single-isomer vitamin E, not a commodity price war already lost.

Instamart is losing ground to Blinkit — slower growth, widening scale gap and rising losses — and needs roughly 2.3x current order value to break even, though management claims losses have peaked.

Blinkit is decisively pulling away from Instamart on order value, store productivity and monthly users, and is doing so profitably with four straight quarters of positive adjusted EBITDA, so habit-driven growth compounds in its favour.

Strong Q2 FY27 momentum — 26% consolidated and 27% India revenue growth, 20% same-store sales growth, robust Candere and store additions — with debt reduction and festive/wedding-season H2 demand expected to support full-year store guidance.

Wockhardt spent 25 years and large R&D sums on antibiotic discovery while peers exited, culminating in FDA approval of Zaynich; the market is re-rating it for this scarce AMR asset despite weak reported growth.

The stock rose because investors may be looking for evidence that June was the bottom, not for strong Q2. Bayview’s first manufacturing agreement makes the underused biologics asset and turnaround story more tangible, though recovery is incomplete.

Rising breaches and tighter regulation haven't translated into gains for India's listed pureplay cybersecurity firms, as enterprise security budgets flow to global platforms and large IT integrators instead.

Quick Heal is shrinking, not benefiting from rising cyberattacks: FY26 revenue fell 7% and it swung to a loss as free Microsoft Defender erodes its consumer antivirus base, while the enterprise pivot grows too slowly to offset.

A weak-key bug destroyed trust in eMudhra's certificate authority business, forcing it to exit global browser-trusted certificates; the hit is ~1% of revenue but the reputational damage drove a 40% stock crash.

Rising renewable energy capacity stresses the grid, so grid automation, demand-supply forecasting, DER management and virtual power plants should become necessary growth areas — though no Indian listed company with meaningful exposure was identified.